STRAIGHT TO THE PLATE -- Nanosys, Bruker team up to get researchers analyzing samples faster

Nanosys Inc., based here, and Billerica, Mass.-based Bruker Daltonics Inc. have entered into a broad research and development collaboration and distribution agreement for Nanosys’ nanotechnology-enabled matrix-free target plates for use primarily with Bruker’s FLEX-series of laser desorption ionization time-of- flight (TOF) mass spectrometers. These Nanosys plates are known as Capture and Analyze NALDI chips.
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
PALO ALTO, Calif.—Nanosys Inc., based here, and Billerica, Mass.-based Bruker Daltonics Inc. have entered into a broad research and development collaboration and distribution agreement for Nanosys' nanotechnology-enabled matrix-free target plates for use primarily with Bruker's FLEX-series of laser desorption ionization time-of- flight (TOF) mass spectrometers. These Nanosys plates are known as Capture and Analyze NALDI chips.
Continue reading below...
Close-up of a researcher using a stylus to draw or interact with digital molecular structures on a blue scientific interface.
ArticlesSpeaking the same molecular language in the age of complex therapeutics
When molecules outgrow the limits of sketches and strings, researchers need a new way to describe and communicate them.
Read More
Under the terms of the agreement, the companies will work together closely on R&D related to the NALDI chips, as well as on applications and assay development. Nanosys has agreed to manufacture and exclusively supply NALDI chips for Bruker laser desorption ionization TOF mass spectrometers, while Bruker Daltonics will market and distribute the NALDI chips worldwide. Financial details of the agreement were not disclosed.
For Nanosys, the advantages of teaming with Bruker were clear, says Calvin Chow, Nanosys' CEO. In addition to being a leader in the area of chemical analysis and life sciences research, he notes, Bruker understands how to take innovative and novel biotech products and get them into high-value markets.
The NALDI chips reportedly provide significant benefits in improving sensitivity, throughput and ease-of-use for the analysis of small molecule drug compounds and other low-mass molecules that have previously been difficult to analyze.
Today, these molecules typically have to be analyzed with LC-MS, noted Bruker and Nanosys in a news release about the deal, adding that this is "time-consuming, less robust and requires more operator training." Using laser desorption ionization, on the other hand, offers such benefits as speedier time to analysis and the ability to decouple the separation and analysis portions of sample preparation, according to Hugh Daniels, director of life sciences R&D for Nanosys.
Continue reading below...
3D illustration of RNA molecules on a gradient blue background.
InfographicsExploring the RNA therapeutics universe
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
Read More
Using the Nanosys plates and laser desorption, one of the advantages for drug discovery and development is that users can archive their chromatography on the plate, Daniels notes, which helps in going back to do specific analyses, rather than having to keep re-running the process in the serial manner associated with more traditional electrospray ionization/LC-column setups.
"You can also remove some upstream sample processing steps by going straight from assay to plate," Daniels says. "So, for example, if you had a sample from a liver microsome assay, you would typically need many preparative steps before putting it on the instrument to analyze it. With this technology, you take the assay from the buffer, put it right on the plate, extract the sample and do your analysis."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up of a researcher using a stylus to draw or interact with digital molecular structures on a blue scientific interface.
When molecules outgrow the limits of sketches and strings, researchers need a new way to describe and communicate them.
Portrait of Scott Weitze, Vice President of Research and Technical Standards at My Green Lab, beside text that reads “Tell us what you know: Bringing sustainability into scientific research,” with the My Green Lab logo.
Laboratories account for a surprising share of global emissions and plastic waste, making sustainability a priority for modern research.
3D illustration of RNA molecules on a gradient blue background.
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
Drug Discovery News September 2025 Issue
Latest IssueVolume 21 • Issue 3 • September 2025

September 2025

September 2025 Issue

Explore this issue